abiraterone + prednisolone + prednisone

This is a combination of three drugs: **abiraterone**, **prednisolone**, and **prednisone**. - **Abiraterone** is a small molecule inhibitor of the enzyme **cytochrome P450 17A1 (CYP17A1)**, which is key to androgen biosynthesis. By inhibiting CYP17A1, abiraterone suppresses the production of androgens from the testes, adrenal glands, and the tumor itself, thereby reducing tumor growth in prostate cancer[1][3][6]. - **Prednisone** and **prednisolone** are synthetic glucocorticoid corticosteroids used as hormone replacement when abiraterone blocks endogenous cortisol synthesis, preventing mineralocorticoid excess and managing side effects such as low potassium, hypertension, and fluid retention[1][2][3][4][6]. - **This specific triple combination (abiraterone + prednisolone + prednisone)** is not established as a standard therapeutic regimen. Abiraterone is typically given with either prednisone or prednisolone, not both at the same time, based on global prescribing practices and regulatory approvals[1][2][3][4][5][6][8].